Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Intensive Care Medicine
Erschienen in: Intensive Care Medicine 7/2004

01.07.2004 | Review

Role of vasopressin in the management of septic shock

verfasst von: Gökhan M. Mutlu, Phillip Factor

Erschienen in: Intensive Care Medicine | Ausgabe 7/2004

Einloggen, um Zugang zu erhalten

Abstract

Vasopressin is a potent vasopressor for improving organ perfusion during septic shock. The rationale for the use of vasopressin is its relative deficiency of plasma levels and hypersensitivity to its vasopressor effects during septic shock. Growing evidence suggests that low-dose (<0.04 U/min) vasopressin is safe and effective for the treatment of vasodilatory shock. Although it is being used more frequently, there are no randomized clinical trials comparing vasopressin as a first-line agent to commonly used vasopressors. However, vasopressin causes arterial smooth muscle cell contraction through a non-catecholamine receptor pathway, thus it represents an attractive adjunct to the management of septic shock, especially when catecholamines are ineffective.
Literatur
1.
Oliver G, Schaefer EA (1895) On the physiological action of extract of pituitary body and certain other glandular organs. J Physiol 18:277–279
2.
Escorsell A, Ruiz del Arbol L, Planas R, Albillos A, Banares R, Cales P, Pateron D, Bernard B, Vinel JP, Bosch J (2000) Multicenter randomized controlled trial of terlipressin versus sclerotherapy in the treatment of acute variceal bleeding: the TEST study. Hepatology 32:471–476
3.
Ortega R, Gines P, Uriz J, Cardenas A, Calahorra B, De Las Heras D, Guevara M, Bataller R, Jimenez W, Arroyo V, Rodes J (2002) Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 36:941–948
4.
Combier E, Levacher S, Letoumelin P, Joseph A, Pourriat JL, de Pouvourville G (1999) Cost-effectiveness analysis of the terlipressin-glycerin trinitrate combination in the pre-hospital management of acute gastro-intestinal haemorrhage in cirrhotic patients. Intensive Care Med 25:364–370
5.
Antoniades C, Auzinger G (2003) Terlipressin and albumin for the hepatorenal syndrome. Hepatology 37:946, Author’s reply 946
6.
Anonymous (2000) Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care. Part 6: Advanced cardiovascular life support: Section 6: Pharmacology II: agents to optimize cardiac output and blood pressure. The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. Circulation 102:I-129–135
7.
Rao VV, Loffler C, Battey J, Hansmann I (1992) The human gene for oxytocin-neurophysin I (OXT) is physically mapped to chromosome 20p13 by in situ hybridization. Cytogenet Cell Genet 61:271–273
8.
Riddell DC, Mallonee R, Phillips JA, Parks JS, Sexton LA, Hamerton JL (1985) Chromosomal assignment of human sequences encoding arginine vasopressin-neurophysin II and growth hormone releasing factor. Somat Cell Mol Genet 11:189–195
9.
Sklar AH, Schrier RW (1983) Central nervous system mediators of vasopressin release. Physiol Rev 63:1243–1280
10.
Lee B, Yang C, Chen TH, al-Azawi N, Hsu WH (1995) Effect of AVP and oxytocin on insulin release: involvement of V1b receptors. Am J Physiol 269:E1095–1100
11.
Birnbaumer M (2000) Vasopressin receptors. Trends Endocrinol Metab 11:406–110
12.
Deen PM, Verdijk MA, Knoers NV, Wieringa B, Monnens LA, van Os CH, van Oost BA (1994) Requirement of human renal water channel aquaporin-2 for vasopressin-dependent concentration of urine. Science 264:92–95
13.
Berl T, Robertson GL (2000) Pathophysiology of water metabolism. In: Brenner BM (ed) Brenner & Rector’s The Kidney. Saunders, Philadelphia, pp 866–924
14.
Fushimi K, Uchida S, Hara Y, Hirata Y, Marumo F, Sasaki S (1993) Cloning and expression of apical membrane water channel of rat kidney collecting tubule. Nature 361:549–552
15.
Nielsen S, DiGiovanni SR, Christensen EI, Knepper MA, Harris HW (1993) Cellular and subcellular immunolocalization of vasopressin-regulated water channel in rat kidney. Proc Natl Acad Sci U S A 90:11663–11667
16.
Reid IA, Schwartz J (1984) Role of vasopressin in the control of blood pressure. In: Martini L, Ganong WF (eds) Frontiers in neuroendocrinology. Raven Press, New York, pp 177–197
17.
Wagner HWJ, Braunwald E (1956) The pressor effect of the antidiuretic principle of the posterior pituitary in orthostatic hypotension. J Clin Invest 35:1412–1418
18.
Ohnishi K, Saito M, Nakayama T, Hatano H, Okuda K (1987) Effects of vasopressin on portal hemodynamics in patients with portal hypertension. Am J Gastroenterol 82:135–138
19.
Morton JJ, Padfield PL (1986) Vasopressin and hypertension in man. J Cardiovasc Pharmacol 8(Suppl 7):S101–106
20.
Abboud FM, Floras JS, Aylward PE, Guo GB, Gupta BN, Schmid PG (1990) Role of vasopressin in cardiovascular and blood pressure regulation. Blood Vessels 27:106–115
21.
Undesser KP, Hasser EM, Haywood JR, Johnson AK, Bishop VS (1985) Interactions of vasopressin with the area postrema in arterial baroreflex function in conscious rabbits. Circ Res 56:410–417
22.
Luk J, Ajaelo I, Wong V, Wong J, Chang D, Chou L, Reid IA (1993) Role of V1 receptors in the action of vasopressin on the baroreflex control of heart rate. Am J Physiol 265:R524–529
23.
Cowley AW Jr, Monos E, Guyton AC (1974) Interaction of vasopressin and the baroreceptor reflex system in the regulation of arterial blood pressure in the dog. Circ Res 34:505–514
24.
Cox BF, Hay M, Bishop VS (1990) Neurons in area postrema mediate vasopressin-induced enhancement of the baroreflex. Am J Physiol 258:H1943–1946
25.
Webb RL, Osborn JW Jr, Cowley AW Jr (1986) Cardiovascular actions of vasopressin: baroreflex modulation in the conscious rat. Am J Physiol 251:H1244–251
26.
Tribollet E, Ueta Y, Heitz F, Marguerat A, Koizumi K, Yamashita H (2002) Up-regulation of vasopressin and angiotensin II receptors in the thalamus and brainstem of inbred polydipsic mice. Neuroendocrinology 75:113–123
27.
Peuler JD, Edwards GL, Schmid PG, Johnson AK (1990) Area postrema and differential reflex effects of vasopressin and phenylephrine in rats. Am J Physiol 258:H1255–1259
28.
Xue B, Gole H, Pamidimukkala J, Hay M (2003) Role of the area postrema in angiotensin II modulation of baroreflex control of heart rate in conscious mice. Am J Physiol Heart Circ Physiol 284:H1003–1007
29.
Mohring J, Glanzer K, Maciel JA Jr, Dusing R, Kramer HJ, Arbogast R, Koch-Weser J (1980) Greatly enhanced pressor response to antidiuretic hormone in patients with impaired cardiovascular reflexes due to idiopathic orthostatic hypotension. J Cardiovasc Pharmacol 2:367–376
30.
Cowley AW Jr, Switzer SJ, Guinn MM (1980) Evidence and quantification of the vasopressin arterial pressure control system in the dog. Circ Res 46:58–67
31.
Xu YJ, Gopalakrishnan V (1991) Vasopressin increases cytosolic free [Ca2+] in the neonatal rat cardiomyocyte. Evidence for V1 subtype receptors. Circ Res 69:239–245
32.
Fujisawa S, Iijima T (1999) On the inotropic actions of arginine vasopressin in ventricular muscle of the guinea pig heart. Jpn J Pharmacol 81:309–312
33.
Laszlo FA, Laszlo F Jr, De Wied D (1991) Pharmacology and clinical perspectives of vasopressin antagonists. Pharmacol Rev 43:73–108
34.
Garcia-Villalon AL, Garcia JL, Fernandez N, Monge L, Gomez B, Dieguez G (1996) Regional differences in the arterial response to vasopressin: role of endothelial nitric oxide. Br J Pharmacol 118:1848–1854
35.
Moursi MM, van Wylen DG, D’Alecy LG (1985) Regional blood flow changes in response to mildly pressor doses of triglycyl desamino lysine and arginine vasopressin in the conscious dog. J Pharmacol Exp Ther 232:360–368
36.
Liard JF, Deriaz O, Schelling P, Thibonnier M (1982) Cardiac output distribution during vasopressin infusion or dehydration in conscious dogs. Am J Physiol 243:H663–669
37.
Vanhoutte PM, Katusic ZS, Shepherd JT (1984) Vasopressin induces endothelium-dependent relaxation of cerebral and coronary, but not of systemic, arteries. J Hypertens Suppl 2:S421–422
38.
Affolter JT, McKee SP, Helmy A, Jones CR, Newby DE, Webb DJ (2003) Intra-arterial vasopressin in the human forearm: pharmacodynamics and the role of nitric oxide. Clin Pharmacol Ther 74:9–16
39.
Bichet DG, Razi M, Lonergan M, Arthus MF, Papukna V, Kortas C, Barjon JN (1988) Hemodynamic and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus. N Engl J Med 318:881–887
40.
Liard JF (1992) cAMP and extrarenal vasopressin V2 receptors in dogs. Am J Physiol 263:H1888–1891
41.
Thibonnier M, Conarty DM, Preston JA, Plesnicher CL, Dweik RA, Erzurum SC (1999) Human vascular endothelial cells express oxytocin receptors. Endocrinology 140:1301–1309
42.
Cronenwett JL, Baver-Neff BS, Grekin RJ, Sheagren JN (1986) The role of endorphins and vasopressin in canine endotoxin shock. J Surg Res 41:609–619
43.
Avontuur JA, Bruining HA, Ince C (1995) Inhibition of nitric oxide synthesis causes myocardial ischemia in endotoxemic rats. Circ Res 76:418–425
44.
Wilson MF, Brackett DJ, Archer LT, Hinshaw LB (1980) Mechanisms of impaired cardiac function by vasopressin. Ann Surg 191:494–500
45.
Brackett DJ, Schaefer CF, Tompkins P, Fagraeus L, Peters LJ, Wilson MF (1985) Evaluation of cardiac output, total peripheral vascular resistance and plasma concentrations of vasopressin in the conscious, unrestrained rat during endotoxemia. Circ Shock 17:273–284
46.
Heyndrickx GR, Boettcher DH, Vatner SF (1976) Effects of angiotensin, vasopressin and methoxamine on cardiac function and blood flow distribution in conscious dogs. Am J Physiol 231:1579–1587
47.
Schmid PG, Abboud FM, Wendling MG, Ramberg ES, Mark AL, Heistad DD, Eckstein JW (1974) Regional vascular effects of vasopressin: plasma levels and circulatory responses. Am J Physiol 227:998–1004
48.
Asfar P, Pierrot M, Veal N, Moal F, Oberti F, Croquet V, Douay O, Gallois Y, Saumet JL, Alquier P, Cales P (2003) Low-dose terlipressin improves systemic and splanchnic hemodynamics in fluid-challenged endotoxic rats. Crit Care Med 31:215–220
49.
Dunser MW, Mayr AJ, Ulmer H, Knotzer H, Sumann G, Pajk W, Friesenecker B, Hasibeder WR (2003) Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation 107:2313–2319
50.
Shelly MP, Greatorex R, Calne RY, Park GR (1988) The physiological effects of vasopressin when used to control intra- abdominal bleeding. Intensive Care Med 14:526–531
51.
Okamura T, Ayajiki K, Fujioka H, Toda N (1999) Mechanisms underlying arginine vasopressin-induced relaxation in monkey isolated coronary arteries. J Hypertens 17:673–678
52.
Russ RD, Walker BR (1992) Role of nitric oxide in vasopressinergic pulmonary vasodilatation. Am J Physiol 262:H743–747
53.
Evora PR, Pearson PJ, Schaff HV (1993) Arginine vasopressin induces endothelium-dependent vasodilatation of the pulmonary artery. V1-receptor-mediated production of nitric oxide. Chest 103:1241–1245
54.
Okamura T, Toda M, Ayajiki K, Toda N (1997) Receptor subtypes involved in relaxation and contraction by arginine vasopressin in canine isolated short posterior ciliary arteries. J Vasc Res 34:464–472
55.
Wallace AW, Tunin CM, Shoukas AA (1989) Effects of vasopressin on pulmonary and systemic vascular mechanics. Am J Physiol 257:H1228–1234
56.
Tang W, Weil MH, Gazmuri RJ, Sun S, Duggal C, Bisera J (1991) Pulmonary ventilation/perfusion defects induced by epinephrine during cardiopulmonary resuscitation. Circulation 84:2101–2107
57.
Loeckinger A, Kleinsasser A, Wenzel V, Mair V, Keller C, Kolbitsch C, Recheis W, Schuster A, Lindner KH (2002) Pulmonary gas exchange after cardiopulmonary resuscitation with either vasopressin or epinephrine. Crit Care Med 30:2059–2062
58.
Pittman QJ, Wilkinson MF (1992) Central arginine vasopressin and endogenous antipyresis. Can J Physiol Pharmacol 70:786–790
59.
Perras B, Pannenborg H, Marshall L, Pietrowsky R, Born J, Lorenz Fehm H (1999) Beneficial treatment of age-related sleep disturbances with prolonged intranasal vasopressin. J Clin Psychopharmacol 19:28–36
60.
Antoni FA (1993) Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age. Front Neuroendocrinol 14:76–122
61.
Tucci JR, Espiner EA, Jagger PI, Lauler DP, Thorn GW (1968) Vasopressin in the evaluation of pituitary-adrenal function. Ann Intern Med 69:191–202
62.
Bugajski J, Gadek-Michalska A, Olowska A, Borycz J, Glod R (1997) Role of nitric oxide in the vasopressin-induced corticosterone secretion in rats. J Physiol Pharmacol 48:805–812
63.
Moos F, Freund-Mercier MJ, Guerne Y, Guerne JM, Stoeckel ME, Richard P (1984) Release of oxytocin and vasopressin by magnocellular nuclei in vitro: specific facilitatory effect of oxytocin on its own release. J Endocrinol 102:63–72
64.
Haslam RJ, Rosson GM (1972) Aggregation of human blood platelets by vasopressin. Am J Physiol 223:958–967
65.
Mannucci PM, Aberg M, Nilsson IM, Robertson B (1975) Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol 30:81–93
66.
Richardson DW, Robinson AG (1985) Desmopressin. Ann Intern Med 103:228–239
67.
Hirsch AT, Dzau VJ, Majzoub JA, Creager MA (1989) Vasopressin-mediated forearm vasodilation in normal humans. Evidence for a vascular vasopressin V2 receptor. J Clin Invest 84:418–426
68.
Raff H (1987) Glucocorticoid inhibition of neurohypophysial vasopressin secretion. Am J Physiol 252:R635–644
69.
Papanek PE, Sladek CD, Raff H (1997) Corticosterone inhibition of osmotically stimulated vasopressin from hypothalamic-neurohypophysial explants. Am J Physiol 272:R158–162
70.
Dunn FL, Brennan TJ, Nelson AE, Robertson GL (1973) The role of blood osmolality and volume in regulating vasopressin secretion in the rat. J Clin Invest 52:3212–3219
71.
Wade CE, Keil LC, Ramsay DJ (1983) Role of volume and osmolality in the control of plasma vasopressin in dehydrated dogs. Neuroendocrinology 37:349–353
72.
Cowley AW Jr, Cushman WC, Quillen EW Jr, Skelton MM, Langford HG (1981) Vasopressin elevation in essential hypertension and increased responsiveness to sodium intake. Hypertension 3:I-93–100
73.
Robinson AG, Verbalis JG (2003) Posterior pituitary gland. In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS (eds) Williams Textbook of Endocrinology. Saunders, Philadelphia, pp 281–330
74.
Robertson GL, Shelton RL, Athar S (1976) The osmoregulation of vasopressin. Kidney Int 10:25–37
75.
Lee ME, Thrasher TN, Keil LC, Ramsay DJ (1986) Cardiac receptors, vasopressin and corticosteroid release during arterial hypotension in dogs. Am J Physiol 251:R614–620
76.
Goetz KL, Wang BC, Sundet WD (1984) Comparative effects of cardiac receptors and sinoaortic baroreceptors on elevations of plasma vasopressin and renin activity elicited by haemorrhage. J Physiol (Paris) 79:440–445
77.
Hammer M, Olgaard K, Schapira A, Bredgaard Sorensen M, Jensen K, Bonde-Petersen F (1988) Hypovolemic stimuli and vasopressin secretion in man. Acta Endocrinol (Copenh) 118:465–473
78.
Leimbach WN Jr, Schmid PG, Mark AL (1984) Baroreflex control of plasma arginine vasopressin in humans. Am J Physiol 247:H638–644
79.
De Lima J, Caillens H, Beaufils M, Ardaillou R (1981) Effects of furosemide-induced plasma volume reduction on plasma antidiuretic hormone in normal and hypertensive subjects. Clin Nephrol 15:246–251
80.
Callahan MF, Ludwig M, Tsai KP, Sim LJ, Morris M (1997) Baroreceptor input regulates osmotic control of central vasopressin secretion. Neuroendocrinology 65:238–245
81.
Goldsmith SR, Cowley AW Jr, Francis GS, Cohn JN (1984) Effect of increased intracardiac and arterial pressure on plasma vasopressin in humans. Am J Physiol 246:H647–651
82.
Robertson GL, Athar S (1976) The interaction of blood osmolality and blood volume in regulating plasma vasopressin in man. J Clin Endocrinol Metab 42:613–620
83.
Schrier RW, Berl T, Anderson RJ (1979) Osmotic and nonosmotic control of vasopressin release. Am J Physiol 236:F321–332
84.
American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:864–874
85.
Sylvester JT, Scharf SM, Gilbert RD, Fitzgerald RS, Traystman RJ (1979) Hypoxic and CO hypoxia in dogs: hemodynamics, carotid reflexes and catecholamines. Am J Physiol 236:H22–28
86.
Benedict CR, Rose JA (1992) Arterial norepinephrine changes in patients with septic shock. Circ Shock 38:165–172
87.
Cumming AD, Driedger AA, McDonald JW, Lindsay RM, Solez K, Linton AL (1988) Vasoactive hormones in the renal response to systemic sepsis. Am J Kidney Dis 11:23–32
88.
Chernow B, Roth BL (1986) Pharmacologic manipulation of the peripheral vasculature in shock: clinical and experimental approaches. Circ Shock 18:141–155
89.
Landry DW, Oliver JA (1992) The ATP-sensitive K+ channel mediates hypotension in endotoxemia and hypoxic lactic acidosis in dog. J Clin Invest 1992:2071–2074
90.
Landry DW, Oliver JA (2001) The pathogenesis of vasodilatory shock. N Engl J Med 345:588–595
91.
Nelson MT, Quayle JM (1995) Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol 268:C799–822
92.
Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345:1368–1377
93.
Chernow B, Rainey TG, Lake CR (1982) Endogenous and exogenous catecholamines in critical care medicine. Crit Care Med 10:409–416
94.
Tsuneyoshi I, Kanmura Y, Yoshimura N (1996) Nitric oxide as a mediator of reduced arterial responsiveness in septic patients. Crit Care Med 24:1083–1086
95.
Fink MP, Homer LD, Fletcher JR (1985) Diminished pressor response to exogenous norepinephrine and angiotensin II in septic, unanesthetized rats: evidence for a prostaglandin-mediated effect. J Surg Res 38:335–342
96.
Hollenberg SM, Tangora JJ, Piotrowski MJ, Easington C, Parrillo JE (1997) Impaired microvascular vasoconstrictive responses to vasopressin in septic rats. Crit Care Med 25:869–873
97.
Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, Frees K, Watt JL, Schwartz DA (2000) TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 25:187–191
98.
Paya D, Stoclet JC (1995) Involvement of bradykinin and nitric oxide in the early hemodynamic effects of lipopolysaccharide in rats. Shock 3:376–379
99.
Thrasher TN, Keil LC (2000) Systolic pressure predicts plasma vasopressin responses to hemorrhage and vena caval constriction in dogs. Am J Physiol Regul Integr Comp Physiol 279:R1035–1042
100.
Wolfer RS, Lovell NH, Brunner MJ (1994) Exogenous arginine vasopressin does not enhance carotid baroreflex control in the conscious dog. Am J Physiol 266:R1510–1516
101.
Robinson JL (1986) Effect of vasopressin and phenylephrine on arterial pressure and heart rate in conscious dogs. Am J Physiol 251:H253–260
102.
Kasting NW, Mazurek MF, Martin JB (1985) Endotoxin increases vasopressin release independently of known physiological stimuli. Am J Physiol 248:E420–424
103.
Wilson MF, Brackett DJ, Tompkins P, Benjamin B, Archer LT, Hinshaw LB (1981) Elevated plasma vasopressin concentrations during endotoxin and E. coli shock. Adv Shock Res 6:15–26
104.
Mastorakos G, Weber JS, Magiakou MA, Gunn H, Chrousos GP (1994) Hypothalamic-pituitary-adrenal axis activation and stimulation of systemic vasopressin secretion by recombinant interleukin-6 in humans: potential implications for the syndrome of inappropriate vasopressin secretion. J Clin Endocrinol Metab 79:934–939
105.
Chikanza IC, Petrou P, Chrousos G (2000) Perturbations of arginine vasopressin secretion during inflammatory stress. Pathophysiologic implications. Ann N Y Acad Sci 917:825–834
106.
Zelazowski P, Patchev VK, Zelazowska EB, Chrousos GP, Gold PW, Sternberg EM (1993) Release of hypothalamic corticotropin-releasing hormone and arginine-vasopressin by interleukin 1 beta and alpha MSH: studies in rats with different susceptibility to inflammatory disease. Brain Res 631:22–26
107.
Sharshar T, Blanchard A, Paillard M, Raphael JC, Gajdos P, Annane D (2003) Circulating vasopressin levels in septic shock. Crit Care Med 31:1752–1758
108.
Sharshar T, Carlier R, Blanchard A, Feydy A, Gray F, Paillard M, Raphael JC, Gajdos P, Annane D (2002) Depletion of neurohypophyseal content of vasopressin in septic shock. Crit Care Med 30:497–500
109.
Goldsmith SR (1998) Vasopressin deficiency and vasodilation of septic shock. Circulation 97:292–293
110.
Landry DW, Levin HR, Gallant EM, Ashton RC, Seo S, D’Alessandro D, Oz MC, Oliver JA (1997) Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 95:1122–1125
111.
Rivier C (2003) Role of nitric oxide in regulating the rat hypothalamic-pituitary-adrenal axis response to endotoxemia. Ann N Y Acad Sci 992:72–85
112.
Godin PJ, Fleisher LA, Eidsath A, Vandivier RW, Preas HL, Banks SM, Buchman TG, Suffredini AF (1996) Experimental human endotoxemia increases cardiac regularity: results from a prospective, randomized, crossover trial. Crit Care Med 24:1117–1124
113.
Moreau R, Hadengue A, Soupison T, Mechin G, Assous M, Roche-Sicot J, Sicot C (1990) Abnormal pressor response to vasopressin in patients with cirrhosis: evidence for impaired buffering mechanisms. Hepatology 12:7–12
114.
Montani JP, Liard JF, Schoun J, Mohring J (1980) Hemodynamic effects of exogenous and endogenous vasopressin at low plasma concentrations in conscious dogs. Circ Res 47:346–355
115.
Patel S, Gaspers LD, Boucherie S, Memin E, Stellato KA, Guillon G, Combettes L, Thomas AP (2002) Inducible nitric-oxide synthase attenuates vasopressin-dependent Ca2+ signaling in rat hepatocytes. J Biol Chem 277:33776–33782
116.
Bucher M, Hobbhahn J, Taeger K, Kurtz A (2002) Cytokine-mediated downregulation of vasopressin V(1A) receptors during acute endotoxemia in rats. Am J Physiol Regul Integr Comp Physiol 282:R979–984
117.
Bartelstone HJ, Nasmyth PA (1965) Vasopressin potentiation of catecholamine actions in dog, rat, cat and rat aortic strip. Am J Physiol 208:754–762
118.
Wakatsuki T, Nakaya Y, Inoue I (1992) Vasopressin modulates K(+)-channel activities of cultured smooth muscle cells from porcine coronary artery. Am J Physiol 263:H491–496
119.
Hamu Y, Kanmura Y, Tsuneyoshi I, Yoshimura N (1999) The effects of vasopressin on endotoxin-induced attenuation of contractile responses in human gastroepiploic arteries in vitro. Anesth Analg 88:542–548
120.
Kusano E, Tian S, Umino T, Tetsuka T, Ando Y, Asano Y (1997) Arginine vasopressin inhibits interleukin-1 beta-stimulated nitric oxide and cyclic guanosine monophosphate production via the V1 receptor in cultured rat vascular smooth muscle cells. J Hypertens 15:627–632
121.
Salzman AL, Vromen A, Denenberg A, Szabo C (1997) K(ATP)-channel inhibition improves hemodynamics and cellular energetics in hemorrhagic shock. Am J Physiol 272:H688–694
122.
Balakrishnan SM, Gopalakrishnan V, McNeill JR (1997) Endothelin contributes to the hemodynamic effects of vasopressin in spontaneous hypertension. Eur J Pharmacol 334:55–60
123.
Levin ER (1996) Endothelins as cardiovascular peptides. Am J Nephrol 16:246–251
124.
Takakura K, Taniguchi T, Muramatsu I, Takeuchi K, Fukuda S (2002) Modification of alpha1 -adrenoceptors by peroxynitrite as a possible mechanism of systemic hypotension in sepsis. Crit Care Med 30:894–899
125.
Umino T, Kusano E, Muto S, Akimoto T, Yanagiba S, Ono S, Amemiya M, Ando Y, Homma S, Ikeda U, Shimada K, Asano Y (1999) AVP inhibits LPS- and IL-1beta-stimulated NO and cGMP via V1 receptor in cultured rat mesangial cells. Am J Physiol 276:F433–441
126.
Nambi P, Whitman M, Gessner G, Aiyar N, Crooke ST (1986) Vasopressin-mediated inhibition of atrial natriuretic factor-stimulated cGMP accumulation in an established smooth muscle cell line. Proc Natl Acad Sci U S A 83:8492–8495
127.
Nambi P, Whitman M, Aiyar N, Crooke ST (1988) Inhibition of formation of cyclic AMP and cyclic GMP by vasopressin in smooth-muscle cells is insensitive to pertussis toxin. Biochem J 254:449–453
128.
Taguchi H, Heistad DD, Chu Y, Rios CD, Ooboshi H, Faraci FM (1996) Vascular expression of inducible nitric oxide synthase is associated with activation of Ca(++)-dependent K+ channels. J Pharmacol Exp Ther 279:1514–1519
129.
Roth BL, Spitzer JA (1987) Altered hepatic vasopressin and alpha 1-adrenergic receptors after chronic endotoxin infusion. Am J Physiol 252:E699–702
130.
Fox AW, May RE, Mitch WE (1992) Comparison of peptide and nonpeptide receptor-mediated responses in rat tail artery. J Cardiovasc Pharmacol 20:282–289
131.
Walker BR (1986) Role of vasopressin in the cardiovascular response to hypoxia in the conscious rat. Am J Physiol 251:H1316–323
132.
Suzuki Y, Satoh S, Oyama H, Takayasu M, Shibuya M (1993) Regional differences in the vasodilator response to vasopressin in canine cerebral arteries in vivo. Stroke 24:1049–1053, discussion 1053–1054
133.
Eisenman A, Armali Z, Enat R, Bankir L, Baruch Y (1999) Low-dose vasopressin restores diuresis both in patients with hepatorenal syndrome and in anuric patients with end-stage heart failure. J Intern Med 246:183–190
134.
Holmes CL, Walley KR, Chittock DR, Lehman T, Russell JA (2001) The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med 27:1416–1421
135.
Cross RB, Trace JW, Vattuone JR (1974) The effect of vasopressin upon the vasculature of the isolated perfused rat kidney. J Physiol 239:435–442
136.
Aiyar N, Nambi P, Crooke ST (1990) Desensitization of vasopressin sensitive adenylate cyclase by vasopressin and phorbol esters. Cell Signal 2:153–160
137.
Rudichenko VM, Beierwaltes WH (1995) Arginine vasopressin-induced renal vasodilation mediated by nitric oxide. J Vasc Res 32:100–105
138.
Edwards RM, Trizna W, Kinter LB (1989) Renal microvascular effects of vasopressin and vasopressin antagonists. Am J Physiol 256:F274–278
139.
Gutkowska J, Jankowski M, Lambert C, Mukaddam-Daher S, Zingg HH, McCann SM (1997) Oxytocin releases atrial natriuretic peptide by combining with oxytocin receptors in the heart. Proc Natl Acad Sci U S A 94:11704–11709
140.
McVicar AJ (1988) Dose-response effects of pressor doses of arginine vasopressin on renal haemodynamics in the rat. J Physiol 404:535–546
141.
Harrison-Bernard LM, Carmines PK (1994) Juxtamedullary microvascular responses to arginine vasopressin in rat kidney. Am J Physiol 267:F249–256
142.
Landry DW, Levin HR, Gallant EM, Seo S, D’Alessandro D, Oz MC, Oliver JA (1997) Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 25:1279–1282
143.
Dunser MW, Mayr AJ, Ulmer H, Ritsch N, Knotzer H, Pajk W, Luckner G, Mutz NJ, Hasibeder WR (2001) The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysis. Anesth Analg 93:7–13
144.
Tsuneyoshi I, Yamada H, Kakihana Y, Nakamura M, Nakano Y, Boyle WA 3rd (2001) Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med 29:487–493
145.
Malay MB, Ashton RC Jr, Landry DW, Townsend RN (1999) Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma 47:699–703, discussion 703–705
146.
Patel BM, Chittock DR, Russell JA, Walley KR (2002) Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 96:576–582
147.
O’Brien A, Clapp L, Singer M (2002) Terlipressin for norepinephrine-resistant septic shock. Lancet 359:1209–1210
148.
Morales D, Madigan J, Cullinane S, Chen J, Heath M, Oz M, Oliver JA, Landry DW (1999) Reversal by vasopressin of intractable hypotension in the late phase of hemorrhagic shock. Circulation 100:226–229
149.
Argenziano M, Chen JM, Choudhri AF, Cullinane S, Garfein E, Weinberg AD, Smith CR Jr, Rose EA, Landry DW, Oz MC (1998) Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. J Thorac Cardiovasc Surg 116:973–980
150.
Argenziano M, Chen JM, Cullinane S, Choudhri AF, Rose EA, Smith CR, Edwards NM, Landry DW, Oz MC (1999) Arginine vasopressin in the management of vasodilatory hypotension after cardiac transplantation. J Heart Lung Transplant 18:814–817
151.
Rosenzweig EB, Starc TJ, Chen JM, Cullinane S, Timchak DM, Gersony WM, Landry DW, Galantowicz ME (1999) Intravenous arginine-vasopressin in children with vasodilatory shock after cardiac surgery. Circulation 100:II-182–106
152.
Morales DL, Gregg D, Helman DN, Williams MR, Naka Y, Landry DW, Oz MC (2000) Arginine vasopressin in the treatment of 50 patients with postcardiotomy vasodilatory shock. Ann Thorac Surg 69:102–106
153.
Dunser MW, Mayr AJ, Stallinger A, Ulmer H, Ritsch N, Knotzer H, Pajk W, Mutz NJ, Hasibeder WR (2002) Cardiac performance during vasopressin infusion in postcardiotomy shock. Intensive Care Med 28:746–751
154.
Argenziano M, Choudhri AF, Oz MC, Rose EA, Smith CR, Landry DW (1997) A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation 96:II-286–290
155.
Chen JM, Cullinane S, Spanier TB, Artrip JH, John R, Edwards NM, Oz MC, Landry DW (1999) Vasopressin deficiency and pressor hypersensitivity in hemodynamically unstable organ donors. Circulation 100:II-244–246
156.
Iwai A, Sakano T, Uenishi M, Sugimoto H, Yoshioka T, Sugimoto T (1989) Effects of vasopressin and catecholamines on the maintenance of circulatory stability in brain-dead patients. Transplantation 48:613–617
157.
Yoshioka T, Sugimoto H, Uenishi M, Sakamoto T, Sadamitsu D, Sakano T, Sugimoto T (1986) Prolonged hemodynamic maintenance by the combined administration of vasopressin and epinephrine in brain death: a clinical study. Neurosurgery 18:565–567
158.
Gold JA, Cullinane S, Chen J, Oz MC, Oliver JA, Landry DW (2000) Vasopressin as an alternative to norepinephrine in the treatment of milrinone-induced hypotension. Crit Care Med 28:249–252
159.
Overand PT, Teply JF (1998) Vasopressin for the treatment of refractory hypotension after cardiopulmonary bypass. Anesth Analg 86:1207–1209
160.
Eyraud D, Brabant S, Nathalie D, Fleron MH, Gilles G, Bertrand M, Coriat P (1999) Treatment of intraoperative refractory hypotension with terlipressin in patients chronically treated with an antagonist of the renin-angiotensin system. Anesth Analg 88:980–984
161.
Minaker KL, Meneilly GS, Youn GJ, Landsberg L, Stoff JS, Robertson GL, Rowe JW (1991) Blood pressure, pulse and neurohumoral responses to nitroprusside-induced hypotension in normotensive aging men. J Gerontol 46:M151–154
162.
Robertson GL (1976) The regulation of vasopressin function in health and disease. Recent Prog Horm Res 33:333–385
163.
Sirinek KR, Levine BA (1988) High-dose vasopressin for acute variceal hemorrhage. Clinical advantages without adverse effects. Arch Surg 123:876–880
164.
Gimson AE, Westaby D, Hegarty J, Watson A, Williams R (1986) A randomized trial of vasopressin and vasopressin plus nitroglycerin in the control of acute variceal hemorrhage. Hepatology 6:410–413
165.
Greenwald RA, Rheingold OJ, Chiprut RO, Rogers AI (1978) Local gangrene: a complication of peripheral Pitressin therapy for bleeding esophageal varices. Gastroenterology 74:744–746
166.
Mogan GR, Wormser GP, Gottfried EB (1980) Infected gangrene. A serious complication of peripheral vasopressin administration. Am J Gastroenterol 73:426–429
167.
Kahn JM, Kress JP, Hall JB (2002) Skin necrosis after extravasation of low-dose vasopressin administered for septic shock. Crit Care Med 30:1899–1901
168.
Bernadich C, Bandi JC, Melin P, Bosch J (1998) Effects of F-180, a new selective vasoconstrictor peptide, compared with terlipressin and vasopressin on systemic and splanchnic hemodynamics in a rat model of portal hypertension. Hepatology 27:351–356
169.
Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichai P, Abergel A, Halimi C, Pauwels M, Bronowicki JP, Giostra E, Fleurot C, Gurnot D, Nouel O, Renard P, Rivoal M, Blanc P, Coumaros D, Ducloux S, Levy S, Pariente A, Perarnau JM, Roche J, Scribe-Outtas M, Valla D, Bernard B, Samuel D, Butel J, Hadengue A, Platek A, Lebrec D, Cadranel JF (2002) Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 122:923–930
170.
Scharte M, Meyer J, Van Aken H, Bone HG (2001) Hemodynamic effects of terlipressin (a synthetic analog of vasopressin) in healthy and endotoxemic sheep. Crit Care Med 29:1756–1760
171.
Medel J, Boccara G, Van de Steen E, Bertrand M, Godet G, Coriat P (2001) Terlipressin for treating intraoperative hypotension: can it unmask myocardial ischemia? Anesth Analg 93:53–55
172.
Westphal M, Stubbe H, Sielenkamper AW, Borgulya R, Van Aken H, Ball C, Bone HG (2003) Terlipressin dose response in healthy and endotoxemic sheep: impact on cardiopulmonary performance and global oxygen transport. Intensive Care Med 29:301–308
173.
Guirao X, Kumar A, Katz J, Smith M, Lin E, Keogh C, Calvano SE, Lowry SF (1997) Catecholamines increase monocyte TNF receptors and inhibit TNF through beta 2-adrenoreceptor activation. Am J Physiol 273:E1203–1208
Metadaten
Titel
Role of vasopressin in the management of septic shock
verfasst von
Gökhan M. Mutlu
Phillip Factor
Publikationsdatum
01.07.2004
Verlag
Springer-Verlag
Erschienen in
Intensive Care Medicine / Ausgabe 7/2004
Print ISSN: 0342-4642
Elektronische ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-004-2283-8

Weitere Artikel der Ausgabe 7/2004

Intensive Care Medicine 7/2004 Zur Ausgabe

Announcements

July 2004

News

The best place to commit the perfect murder

Original

Neurologic status, cough, secretions and extubation outcomes

Original

Pattern of lung emptying and expiratory resistance in mechanically ventilated patients with chronic obstructive pulmonary disease

Correspondence

Author’s reply to the comments by de Rooij and de Jonge

Original

Estimation of left ventricular systolic function by single transpulmonary thermodilution

Neu im Fachgebiet AINS

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

18.04.2024 | Pädiatrische Notfallmedizin | Nachrichten

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

17.04.2024 | Postoperative nausea and vomiting | Nachrichten

Hochrisiko-Eingriffe für postoperative Übelkeit

11.04.2024 | Rückenschmerzen | Nachrichten

Diclofenac-Gel versus Ibuprofen bei akuten Rückenschmerzen
weitere anzeigen

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren